Rhumbline Advisers Sells 18,499 Shares of Danaher Corporation $DHR

Rhumbline Advisers trimmed its holdings in shares of Danaher Corporation (NYSE:DHR) by 1.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,064,218 shares of the conglomerate’s stock after selling 18,499 shares during the period. Rhumbline Advisers owned approximately 0.15% of Danaher worth $210,226,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in DHR. CenterBook Partners LP raised its stake in Danaher by 106.5% during the second quarter. CenterBook Partners LP now owns 12,413 shares of the conglomerate’s stock valued at $2,452,000 after buying an additional 6,401 shares during the last quarter. Mufg Securities Americas Inc. grew its stake in shares of Danaher by 24.6% in the second quarter. Mufg Securities Americas Inc. now owns 14,117 shares of the conglomerate’s stock worth $2,789,000 after acquiring an additional 2,788 shares during the last quarter. Evelyn Partners Investment Management Services Ltd increased its holdings in shares of Danaher by 6,906.8% during the second quarter. Evelyn Partners Investment Management Services Ltd now owns 3,083 shares of the conglomerate’s stock valued at $609,000 after acquiring an additional 3,039 shares in the last quarter. Evelyn Partners Investment Management LLP increased its holdings in shares of Danaher by 1,105.7% during the second quarter. Evelyn Partners Investment Management LLP now owns 90,751 shares of the conglomerate’s stock valued at $17,927,000 after acquiring an additional 83,224 shares in the last quarter. Finally, Evelyn Partners Investment Management Europe Ltd raised its position in shares of Danaher by 217.0% in the 2nd quarter. Evelyn Partners Investment Management Europe Ltd now owns 3,192 shares of the conglomerate’s stock worth $630,000 after purchasing an additional 2,185 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Trading Up 2.3%

Shares of Danaher stock opened at $227.34 on Friday. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The company’s fifty day simple moving average is $208.58 and its 200-day simple moving average is $201.97. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The stock has a market capitalization of $160.58 billion, a PE ratio of 46.88, a P/E/G ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last released its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.17. The company had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.Danaher’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.71 earnings per share. As a group, equities analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were paid a dividend of $0.32 per share. The ex-dividend date was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is presently 26.39%.

Insider Buying and Selling at Danaher

In related news, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the transaction, the senior vice president owned 14,553 shares in the company, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares in the company, valued at $552,352.50. This represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 30,248 shares of company stock valued at $6,609,663 over the last 90 days. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on DHR shares. Barclays upped their price target on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Cowen reiterated a “buy” rating on shares of Danaher in a research note on Wednesday, October 22nd. Bank of America reduced their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Robert W. Baird set a $247.00 target price on shares of Danaher in a research note on Wednesday, October 22nd. Finally, JPMorgan Chase & Co. lifted their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average price target of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.